<div id="readability-page-1"><p>PureTech Health (NASDAQ:PRTC - Get Free Report) issued its earnings results on Wednesday. The company reported ($1.35) earnings per share for the quarter, topping the consensus estimate of ($1.94) by $0.59, FiscalAI reports. The firm had revenue of $1.40 million during the quarter, compared to analysts' expectations of $1.90 million.</p><div><p><span></span><span>Get <strong>PureTech Health</strong> alerts:</span></p></div><p>Here are the key takeaways from PureTech Health's conference call:</p><ul>   <li>PureTech has a refined strategy to operate a <strong>leaner hub</strong>, voluntarily delist from Nasdaq to reduce costs, launch founded entities earlier to leverage external capital, and increase capital returns to shareholders.</li>   <li><strong>Celea Therapeutics</strong> fundraising is described as &#34;substantially complete&#34; with a targeted close in early Q3 2026 to support a Phase III SURPASS‑IPF trial for deupirfenidone, a near‑term value inflection for PureTech.</li>   <li><strong>Gallop</strong>'s LYT‑200 reported positive Phase I‑B top‑line data (12 mg/kg dose, good safety, dose‑dependent activity), prompting prioritization of relapsed refractory high‑risk MDS and plans to engage the FDA for a potentially registration‑enabling trial while seeking external capital.</li>   <li>PureTech held approximately <strong>$248.1m</strong> in cash and equivalents as of March 31, 2026 and expects operational runway at least through the end of 2028, inclusive of anticipated participation in Celea and Gallop financings.</li>   <li>The innovation engine will follow the LIFE model to progress concept‑stage programs with modest capital, targeting up to two development candidates over the next three years (focus areas include CNS and capital‑efficient small molecules).</li> </ul><h2>PureTech Health Trading Down 4.9%</h2><p>NASDAQ:PRTC traded down $0.89 during mid-day trading on Wednesday, hitting $17.25. The company had a trading volume of 13,352 shares, compared to its average volume of 4,447. The business has a fifty day simple moving average of $16.87 and a 200-day simple moving average of $17.25. PureTech Health has a 1 year low of $14.50 and a 1 year high of $19.92. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Separately, Weiss Ratings  reaffirmed a &#34;sell (d)&#34; rating on shares of PureTech Health in a research report on Tuesday, April 21st. One analyst  has rated the stock with a Sell rating,  According to data from MarketBeat, the stock currently has an average rating of &#34;Sell&#34;.</p><p><b>Get Our Latest Stock Analysis on PureTech Health</b></p><h2>Institutional Inflows and Outflows</h2><p>An institutional investor recently raised its position in PureTech Health stock. Pentwater Capital Management LP lifted its holdings in shares of  PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Free Report) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 75,000 shares of the company's stock after acquiring an additional 25,000 shares during the quarter. Pentwater Capital Management LP owned 0.31% of PureTech Health worth $1,388,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own  0.04% of the company's stock. </p><h2>About PureTech Health</h2> (Get Free Report)<p>PureTech Health <span>NASDAQ: PRTC<span></span></span> is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders. </p><p>PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than PureTech Health</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2><p>Before you consider PureTech Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p><p>While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRTC

PRTCY

<p>PureTech Health (NASDAQ:PRTC) reported quarterly earnings of ($1.35) EPS, exceeding estimates of ($1.94) by $0.59. Revenue was $1.40 million, below the expected $1.90 million. The company plans to delist from Nasdaq to cut costs and aims to launch entities earlier for capital leverage. PureTech has $248.1 million in cash, ensuring operational runway through 2028. Despite a 4.9% drop in stock price to $17.25, analysts maintain a "sell" rating, with institutional investors increasing their holdings. PureTech focuses on developing first-in-class medicines across various therapeutic areas.</p>

Market Beat

PureTech Health (NASDAQ:PRTC) Posts Quarterly Earnings Results, Beats Estimates By $0.59 EPS